Anthera Pharmaceuticals to Report 2015 Second Quarter and Operational Update on August 10
30 juil. 2015 17h10 HE
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., July 30, 2015 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced that it plans to issue a press release reporting its 2015 second quarter and operational...
Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
14 juil. 2015 12h05 HE
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., July 14, 2015 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH), today announced that it has completed the previously announced underwritten public offering of 3,833,334...
Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
09 juil. 2015 09h00 HE
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., July 9, 2015 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced the pricing of an underwritten public offering of 3,333,334 shares of its common...
Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
08 juil. 2015 16h02 HE
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., July 8, 2015 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced that it intends to offer and sell shares of its common stock in an underwritten...
Anthera Pharmaceuticals Added to the Russell 2000(R) and Russell 3000(R) Indexes
26 juin 2015 18h30 HE
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., June 26, 2015 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH), a biopharmaceutical company focused on developing and commercializing products to treat serious and...
Anthera Pharmaceuticals Has Reached Enrollment Target in CHABLIS-SC1 Phase 3 Clinical Trial With Blisibimod
16 juin 2015 17h01 HE
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., June 16, 2015 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced that it has met the enrollment target of its CHABLIS-SC1 Phase 3 clinical trial...
Anthera Pharmaceuticals Announces Additional Data on Patient-Reported Outcomes From Phase 2b PEARL-SC Blisibimod Study
04 juin 2015 16h30 HE
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., June 4, 2015 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH), a biopharmaceutical company focused on advancing the development and commercialization of innovative...
Anthera Pharmaceuticals to Present at Annual Jefferies Healthcare Conference
27 mai 2015 13h30 HE
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., May 27, 2015 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH), a biopharmaceutical company focused on advancing the development and commercialization of innovative...
Anthera Pharmaceuticals Reports 2015 First Quarter and Operational Update
11 mai 2015 17h30 HE
|
Anthera Pharmaceuticals, Inc.
Completed Interim Analysis from Phase 3 Trial with Blisibimod for Systematic Lupus Erythematosus
Completed Interim Analysis from Phase 2/3 Trial with Blisibimod for IgA...